Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

72 trials found

Recruiting NA 36,503 target

Supraglottic Airway for Resuscitation Trial

Children's Hospital of Philadelphia

NCT07150923

Recruiting 5,000 target

Cardiogenic Shock Working Group Registry

Tufts Medical Center

NCT04682483

Recruiting Phase 3 4,000 target

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

University of Manitoba

NCT05848713

Recruiting NA 3,290 target

Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy

University of Rochester

NCT06543446

Recruiting Phase 3 3,200 target

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Icahn School of Medicine at Mount Sinai

NCT04045665

Recruiting NA 3,000 target

Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders

University of Michigan

NCT05929703

Recruiting NA 2,700 target

I-DECIDE After Bronchiolitis Hospitalization

Seattle Children's Hospital

NCT07243652

Recruiting Phase 3 2,400 target

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Merck Sharp & Dohme

NCT06966700

Recruiting 2,150 target

CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting

Corcym S.r.l

NCT05002543

Recruiting 2,020 target

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Guardant Health

NCT05059444

Recruiting NA 1,440 target

Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery

Unity Health Toronto

NCT04754022

Recruiting Phase 3 1,123 target

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Merck Sharp & Dohme

NCT06952504

Recruiting NA 1,100 target

IMPRoving Outcomes in Vascular DisEase - Aortic Dissection

Duke University

NCT06087029

Recruiting Phase 3 1,095 target

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Genmab

NCT06191744

Recruiting NA 1,094 target

Brain Oxygen Optimization in Severe TBI, Phase 3

University of Michigan

NCT03754114

Recruiting Phase 3 1,000 target

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Olema Pharmaceuticals

NCT07085767

Recruiting NA 1,000 target

Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors

Johns Hopkins University

NCT03803423

Recruiting Phase 2 920 target

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

NCT04589845

Recruiting NA 842 target

CTSN Embolic Protection Trial

Icahn School of Medicine at Mount Sinai

NCT06027788

Recruiting Phase 3 770 target

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Merck Sharp & Dohme

NCT06824467

Recruiting Phase 3 714 target

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Pfizer

NCT06758401

Recruiting Phase 3 700 target

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

AstraZeneca

NCT07044336

Recruiting Phase 3 675 target

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Merck Sharp & Dohme

NCT07190248

Recruiting Phase 3 614 target

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Merck Sharp & Dohme

NCT06170788

Recruiting Phase 2 590 target

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Bristol-Myers Squibb

NCT07063745

Recruiting Phase 3 558 target

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

BioNTech SE

NCT07173751

Recruiting NA 550 target

Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial

Medtronic Cardiovascular

NCT05378347

Recruiting Phase 3 520 target

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

GlaxoSmithKline

NCT06679101

Recruiting 500 target

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

Wake Forest University Health Sciences

NCT07215624

Recruiting Phase 4 500 target

AWARE: Management of ADHD in Autism Spectrum Disorder

Daniel Coury

NCT05916339

Recruiting Phase 3 500 target

Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

NYU Langone Health

NCT05591118

Recruiting Phase 3 466 target

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Incyte Corporation

NCT07214779

Recruiting Phase 3 450 target

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Ivy Brain Tumor Center

NCT06388733

Recruiting NA 450 target

Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)

Annetine Gelijns

NCT05051033

Recruiting Phase 3 410 target

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

AVEO Pharmaceuticals

NCT06064877

Recruiting Phase 2 400 target

Nectero EAST System Clinical Study

Nectero Medical

NCT06001918

Recruiting Phase 3 400 target

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Day One Biopharmaceuticals

NCT05566795

Recruiting 400 target

Immunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS)

MaineHealth

NCT02664831

Recruiting Phase 3 390 target

Abatacept in Immune Checkpoint Inhibitor Myocarditis

Massachusetts General Hospital

NCT05335928

Recruiting Phase 2 375 target

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Dana-Farber Cancer Institute

NCT04569747

Recruiting Phase 3 360 target

Standard Versus High Dose ED-Initiated Buprenorphine Induction

Yale University

NCT06494904

Recruiting Phase 3 351 target

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

BeOne Medicines

NCT07043400

Recruiting 300 target

Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy

Dana-Farber Cancer Institute

NCT04968834

Recruiting Phase 1 285 target

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Genentech

NCT07100106

Recruiting Phase 2 274 target

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Janssen Research & Development

NCT06635148

Recruiting NA 250 target

PRIMARY Ancillary Substudy

Annetine Gelijns

NCT07103733

Recruiting Phase 4 188 target

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Genentech

NCT04853251

Recruiting NA 180 target

AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

Shape Memory Medical

NCT06029660

Recruiting Phase 3 180 target

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Ardelyx

NCT05643534

Recruiting 160 target

Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects

Biometry

NCT07228026

Recruiting NA 155 target

The THOR IDE Study

Philips Clinical & Medical Affairs Global

NCT05916950

Recruiting Phase 2 150 target

Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior

University of Utah

NCT05767385

Recruiting 150 target

Biliary Atresia Research Network Northeast

Yale University

NCT06184971

Recruiting 150 target

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

Bayer

NCT04142437

Recruiting NA 150 target

Strategies to Improve Well-Being and Diabetes Management

Elizabeth Scharnetzki

NCT06348238

Recruiting Phase 1 148 target

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Alliance Foundation Trials

NCT04486352

Recruiting Phase 2 125 target

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Jazz Pharmaceuticals

NCT07102381

Recruiting Phase 2 120 target

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Bristol-Myers Squibb

NCT05076175

Recruiting Phase 2 110 target

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Dana-Farber Cancer Institute

NCT04468061

Recruiting NA 100 target

Supporting Health in Veterans With Heart Failure

Florida State University

NCT05839067

Recruiting NA 97 target

Education & Mentorship of Advanced Practice Providers to Increase Community-based Research Within the NCORP Network, COACH-APP Trial

Wake Forest University Health Sciences

NCT06904391

Recruiting Phase 2 92 target

Study of DONQ52 in Active Celiac Disease

Chugai Pharmaceutical

NCT07239336

Recruiting 80 target

Studies of Neuregulin/ERBB Signaling in Human Heart

Douglas B. Sawyer

NCT02820233

Recruiting NA 80 target

Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D)

Treace Medical Concepts

NCT05587569

Recruiting Phase 1 75 target

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics

NCT04094610

Recruiting 60 target

Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

Ensoma

NCT06605378

Recruiting Phase 1 60 target

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

Janssen Research & Development

NCT07227025

Recruiting Phase 2 60 target

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Inhye Ahn

NCT06333262

Recruiting Phase 3 50 target

Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting

XenoTherapeutics

NCT06223269

Recruiting Phase 2 45 target

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Dana-Farber Cancer Institute

NCT05168930

Recruiting 30 target

Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies

Addario Lung Cancer Medical Institute

NCT06486428

Recruiting Phase 4 20 target

Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

Madeleine Puissant

NCT06569212

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →